We hope that the information reported in this review will be useful to researchers dedicated to the design and synthesis of novel dual PTP1B/α-glucosidase inhibitors to be used routinely for the treatment of patients affected by T2D, obesity, and metabolic syndrome. Here, PTPN1 is linked to Obesity.